Rosabulin is a small molecule drug. Rosabulin is under investigation in clinical trial NCT00276913 (A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors). Rosabulin has a monoisotopic molecular weight of 400.1 Da.
Rosabulin, 10 mM in DMSO3-[(4-cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-α-oxo-1-indolizineacetamide1-Indolizineacetamide, 3-[(4-cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-α-oxo-